News
XOMA
29.24
+1.11%
0.32
Weekly Report: what happened at XOMA last week (0715-0719)?
Weekly Report · 4d ago
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Seeking Alpha · 07/19 12:30
Weekly Report: what happened at XOMA last week (0708-0712)?
Weekly Report · 07/15 11:29
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
Zevra Therapeutics Inc.’s arimoclomol for Niemann-Pick disease type C (NPC) is expected to be reviewed by the FDA in September. The company acquired arimclomol from Orphazyme for $12.8 million. William Blair reiterates the Outperform rating for Zevra.
Benzinga · 07/09 19:27
Demystifying XOMA: Insights From 5 Analyst Reviews
XOMA Corp is a biotechnology royalty aggregator. The company has an average 12-month price target of $67.2. 5 analysts have released ratings for XOMA in the past three months. The average price target is a decrease from the previous average of $74.00. XomA Corp has a positive revenue growth rate of 240.96% over the past decade.
Benzinga · 07/09 14:01
XOMA CORP - FILED AMENDMENT TO AMENDED CERTIFICATE OF INCORPORATION TO CHANGE NAME OF CO FROM "XOMA CORPORATION" TO "XOMA ROYALTY CORPORATION"
Reuters · 07/09 12:08
Strong Buy Rating for Xoma on Vabysmo’s Market Approval and Financial Prospects
TipRanks · 07/09 10:17
Weekly Report: what happened at XOMA last week (0701-0705)?
Weekly Report · 07/08 11:31
XOMA Corp's 8.625% Series A Cumulative Perpetual Preferred Stock Shares Cross 8.5% Yield Mark
NASDAQ · 07/03 18:05
Weekly Report: what happened at XOMA last week (0624-0628)?
Weekly Report · 07/01 11:32
XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Seeking Alpha · 06/29 06:31
Weekly Report: what happened at XOMA last week (0617-0621)?
Weekly Report · 06/24 11:40
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
NASDAQ · 06/21 11:54
Press Release: XOMA Declares Quarterly Preferred Stock Dividends
Dow Jones · 06/20 11:30
Weekly Report: what happened at XOMA last week (0610-0614)?
Weekly Report · 06/17 11:31
XOMA RECEIVES $8.1 MILLION MILESTONE RELATED TO DAY ONE BIOPHARMACEUTICALS’ SALE OF ITS PRIORITY REVIEW VOUCHER
Reuters · 06/12 11:30
Weekly Report: what happened at XOMA last week (0603-0607)?
Weekly Report · 06/10 11:33
ImmunityBio, LadRx end licensing deal for cancer drug
Healthcare ImmunityBio, LadRx end licensing deal for cancer drug for aldoxorubicin. The drug is an investigational therapy targeted at soft tissue sarcoma and other cancers. XOMA Corporation and ImmunityBio revise their 2023 royalty agreement related to the drug.
Seeking Alpha · 06/04 11:06
Xoma’s Strong Monetization and Royalty Potential Justify Buy Rating
TipRanks · 06/04 08:08
LadRx And ImmunityBio Agree To Terminate Aldoxorubicin License
NASDAQ · 06/04 01:39
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).